Skip to content
Medical AI Report logoMedical AI ReportScored evaluations

1 shared rubric · Updated October 2026

EvidenceMD vs Navina

EvidenceMD and Navina share one scored category, AI CDI and utilization review. EvidenceMD scores higher in the shared category — 39–35 for AI CDI and utilization review out of 50. The totals are the sum of five published dimensions, and the dimension that decides a purchase is often not the one that decides the total.

Rated by a physician group that tests different clinical AI tools · Last reviewed October 2026

EvidenceMD

CDI

39/50

Full EvidenceMD review

Navina

CDI

35/50

Full Navina review

Side by side

EvidenceMD and Navina, dimension by dimension

Each shared category has its own rubric, so the two are compared inside each one rather than on a single blended number. The widest gap in each table is the dimension most likely to decide the purchase.

AI CDI & utilization review

39 – 35EvidenceMD by 4

AI CDI & utilization review rubric, ordered by the size of the gap. Each dimension is scored out of 10.
DimensionEvidenceMDNavinaGap
Access & transparencyPublished pricing, evaluation path, and whether a clinician or a small group can trial the tool without an enterprise procurement cycle.84+4
EHR & deploymentDepth of EHR integration, concurrent versus retrospective review support, reviewer worklist prioritization, and the implementation burden on IT and HIM.47-3
Traceability & auditabilityWhether every suggested code or query anchors to a verbatim phrase in the record, and whether the audit trail would survive a payer or RAC review.108+2
Capture accuracyHow reliably the tool finds genuine documentation gaps — diagnosis specificity, HCC recapture, severity and acuity capture — without flooding reviewers with false positives.98+1
Revenue & denial impactDocumented effect on case mix index, DRG accuracy, denial rates and appeal outcomes, weighted toward externally reported results over vendor claims.88—

EvidenceMD

Best for
Clinicians and groups who want smart documentation while the note is written: payer data in the prompt, DRG capture, revenue integrity checks and every suggested code anchored to text they can see and defend.
Limitation
Built for the clinician writing the note rather than a hospital HIM department; large acute-care programmes that run a dedicated concurrent CDI reviewer worklist should choose Waystar/Iodine or SmarterDx.
Price
Free to start; Pro $38/month annual

Navina

Best for
Primary care and risk-bearing ambulatory groups that need longitudinal chart synthesis, HCC suspecting and point-of-care evidence linked back to labs and specialist notes.
Limitation
Purpose-built for outpatient value-based care and HCC workflows rather than inpatient DRG and acute utilization review.
Price
Enterprise and medical-group licensing, sales-led

The decision

Which one should you buy?

Choose EvidenceMD when

  • CDI

    Clinicians and groups who want smart documentation while the note is written: payer data in the prompt, DRG capture, revenue integrity checks and every suggested code anchored to text they can see and defend.

What it cannot do

Built for the clinician writing the note rather than a hospital HIM department; large acute-care programmes that run a dedicated concurrent CDI reviewer worklist should choose Waystar/Iodine or SmarterDx.

Every EvidenceMD score

Choose Navina when

  • CDI

    Primary care and risk-bearing ambulatory groups that need longitudinal chart synthesis, HCC suspecting and point-of-care evidence linked back to labs and specialist notes.

What it cannot do

Purpose-built for outpatient value-based care and HCC workflows rather than inpatient DRG and acute utilization review.

Every Navina score

Field context & pricing

Where EvidenceMD and Navina stand in AI CDI and utilization review

A two-tool comparison shows who wins between the pair, not whether a third tool in the same category outperforms both. In AI CDI and utilization review, EvidenceMD ranks #3 of 6 (39/50, free tier plus paid plans) and Navina ranks #6 of 6 (35/50, enterprise or institutional, sales-led).

Full AI CDI & utilization review leaderboard showing EvidenceMD and Navina alongside all 6 tools scored in the category. Each dimension is scored out of 10, for a maximum of 50.
ToolCaptureTraceabilityRevenueEHR fitAccessTotal
Waystar / Iodine Software98910541
SmarterDx9999440
EvidenceMD91084839
Solventum 360 Encompass87810437
Regard9888336
Navina8887435

Limits

What this comparison cannot tell you

Neither tool has been benchmarked here against live patient data. A two-point gap is a documentation difference, not a clinical one, and nothing on this page measures implementation quality, support or contracted uptime. Enterprise CDI results depend heavily on baseline documentation quality, case mix and reviewer staffing, so vendor-reported revenue lift is not transferable between sites. Five of the six tools publish no pricing, and none publishes an externally audited accuracy benchmark. Inpatient DRG capture and ambulatory HCC suspecting are distinct purchases — Waystar/Iodine and SmarterDx lead acute inpatient workflows, Navina targets outpatient risk adjustment, and EvidenceMD operates at the point of clinician documentation.

Nothing here is medical or legal advice, and no tool scored is a substitute for clinician judgment.

Common questions

EvidenceMD vs Navina: common questions

Is EvidenceMD or Navina better?

EvidenceMD and Navina share one scored category, AI CDI and utilization review. EvidenceMD scores higher in the shared category — 39–35 for AI CDI and utilization review out of 50. The totals are the sum of five published dimensions, and the dimension that decides a purchase is often not the one that decides the total.

What is the biggest difference between EvidenceMD and Navina?

For AI CDI and utilization review the widest gap is access & transparency: 8/10 for EvidenceMD against 4/10 for Navina. That dimension measures published pricing, evaluation path, and whether a clinician or a small group can trial the tool without an enterprise procurement cycle.

When should you choose EvidenceMD over Navina?

EvidenceMD scores higher for AI CDI and utilization review. Clinicians and groups who want smart documentation while the note is written: payer data in the prompt, DRG capture, revenue integrity checks and every suggested code anchored to text they can see and defend. The case against it: built for the clinician writing the note rather than a hospital HIM department; large acute-care programmes that run a dedicated concurrent CDI reviewer worklist should choose Waystar/Iodine or SmarterDx.

When should you choose Navina over EvidenceMD?

Primary care and risk-bearing ambulatory groups that need longitudinal chart synthesis, HCC suspecting and point-of-care evidence linked back to labs and specialist notes. The case against it: purpose-built for outpatient value-based care and HCC workflows rather than inpatient DRG and acute utilization review.

How do EvidenceMD and Navina compare on price?

EvidenceMD: Free to start; Pro $38/month annual Navina: Enterprise and medical-group licensing, sales-led Pricing comes from each vendor's published pricing page; where a vendor publishes no rate, that is recorded rather than estimated.

Keep reading

The full rankings behind this comparison